11th IAS Conference on HIV Science (IAS 2021)
1 August 2021. Related: Conference reports.
18 – 21 July 2021
Introduction
The 11th IAS Conference on HIV Science held from 18 – 21 July 2021 was organised as a virtual meeting, though originally due to be held in Berlin.
These biennial meetings usually include more than 5,000 delegates and alternate with the larger IAS World AIDS Conferences.
The programme is already posted online to one IAS website the with open access already available for the abstracts. This portal includes a search engine that includes URLs for each study.
https://www.ias2021.org/the-programme
The conference format has adapted to a virtual format by reducing the number of oral abstract to three and including plenty of time for live questions and discussion afterwards. This makes it much easier to focus in more depth on the most important studies.
Unfortunately, the open access programme doesn’t link to a second stand-alone conference use to host webcasts, posters and other resources.
This second website uses a different portal that restricts access to registered delegates, at least while the conference is running. This website doesn’t provide URLs to presentations or abstracts. PDF versions of posters are not currently available, although this might change in the future.
https://conference.ias2021.org
As with all IAS conferences, there are many related workshops before and during the conference, including on paediatric care and cure related research. Access to many of the satellite meetings is restricted to healthcare professionals.
This year the conference has a strong programme including research on PrEP, new HIV drugs for treatment, cure-related research, paediatrics and COVID-19. Many of the session cover healthcare for key populations.
Short rapporteur summaries for key sessions are available as open access at the end of each day.
https://www.ias2021.org/rapporteurs
Early reports in HTB will be added below.
- IAS 2021: HIV pipeline drugs: CAB/RPV LA, fostemsavir, paediatric dolutegravir, lenacapavir, islatravir, MK-8507 and albuvirtide
- IAS 2021: Proving efficacy of next generation PrEP: counterfactual controls in lenacapavir and islatravir studies
- IAS 2021: IAS 2021: WHO report links HIV to 30% increased mortality from COVID-19: based on South African data
- IAS 2021: New demands for better transgender heath care: No data no more
This page was first posted on 17 July 2021 and is updated as new reports are added.